TY -的T1 -第二阶段多个提升吸入的剂量研究pan-JAK抑制剂nezulcitinib (td - 0903)在严重COVID-19 JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00673 -2021欧元六世- 58 - 4 SP - 2100673 AU -戴夫·辛格莫斯卡伦科盟盟-马克西姆虚假盟双方-罗伯特主盟-埃德蒙·J·莫兰盟-格伦·d·火山口AU -大卫·l·Bourdet盟盟内森·d·Pfeifer杰克吸引非盟-兰德考夫曼盟David A . Lombardi盟盟-艾米丽翁y盟黎-阿什利丘鹬AU -布雷特Haumann盟Rajeev匣钵Y1 - 2021/10/01 UR - //www.qdcxjkg.com/content/58/4/2100673.abstract N2 - 2019 (COVID-19)的特点是严重的冠状病毒疾病肺炎过度系统性炎症,称为“细胞因子风暴”[1 - 3]。地塞米松治疗降低患者死亡率COVID-19接收呼吸支持和照顾标准严重COVID-19 (4、5)。然而,肺部炎症,使COVID-19发病率和死亡率[3],坚持尽管皮质类固醇可以使用[6、7]。Janus激酶(激酶)抑制块由许多细胞因子信号在不同的细胞类型,提供广泛的免疫调节[8]。口服JAK-1/2抑制剂baricitinib结合抗病毒remdesivir显示严重患者临床疗效COVID-19 [9]。直接交付木菠萝抑制通过吸入肺能克服corticosteroid-resistant肺部炎症[10],提供潜在的改进反应过度系统性免疫抑制的同时最小化风险。这部小说吸入pan-JAK抑制剂nezulcitinib (td - 0903)设计目标所有木菠萝亚型(JAK1, JAK2、JAK3 TYK2;−日志抑制常数≥9.2)和优化交付到肺部,同时限制系统性风险(r .萨那和同事;未发表的结果:抽象的提交人国际大会,2021)。我们报告的结果完成了部分文章的第一篇第二阶段试验(NCT04402866)住院患者严重COVID-19。The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus placebo https://bit.ly/35Xs1RfThe authors and Theravance Biopharma, Inc., thank the patients and their families for their participation and Kyla Kennedy for clinical operations. Dave Singh, Robert Lord and Ashley Woodcock are supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). ER -